Secretome Therapeutics starts Phase 2 THRIVE-2 study in Duchenne muscular dystrophy

The study is open for enrollment and will evaluate STM-01 in patients with Duchenne muscular dystrophy. Secretome said the first patient is expected to enroll imminently.